Early Access Program

Early Access Programs Currently Open

Givosiran for the treatment of acute hepatic porphyria (AHP)

Patisiran for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis

Lumasiran for the treatment of primary hyperoxaluria type 1 (PH1)

SIGN UP FOR EMAIL UPDATES

Receive news and updates on the work at Alnylam that affects you most.